AUG 13, 2026 · JOURNAL ARTICLE
TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776 ‐Altered Subtype of HER2 ‐Mutant NSCLC
Cancer Science
A validated two-stage clinicogenomic discovery study identifying a recurrent co-mutation association in a molecularly defined NSCLC subtype, but limited by small sample sizes in functional or treatment-outcome validation and lack of prospective clinical utility data.
Reported
Odds ratio (TERT enrichment in ER…2.40
95% CI (TERT enrichment)1.12–4.70
p-value (TERT enrichment discover…0.017